Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion to Bolster Myelofibrosis Program
Ipsen has agreed to acquire privately held Kartos Therapeutics in a transaction valued at up to $1.75 billion. The French drugmaker will make a $450 million upfront payment and may pay up to $1.3 billion more tied to regulatory and sales milestones. The deal adds navtemadlin, a late-stage candidate for myelofibrosis, to Ipsen's oncology portfolio. …